Oncolytic poliovirus therapy and immunization with poliovirus-infected cell lysate induces potent antitumor immunity against neuroblastoma in vivo

International Journal of Oncology

Volumn 38, Issue 1, 2011, Pages 81-87

  Toyoda, Hidemi ^a   Wimmer, Eckard ^a   Cello, Jeronimo ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Immunity; Neuroblastoma; Oncolytic poliovirus; Viral oncolysate

Indexed keywords

ONCOLYTIC VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL LYSATE; CYTOTOXICITY; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; SPLEEN CELL; TUMOR IMMUNITY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; IMMUNIZATION; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, TRANSGENIC; NEUROBLASTOMA; ONCOLYTIC VIROTHERAPY; POLIOVIRUS; RECEPTORS, VIRUS; SPLEEN;

EID: 78650809359     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000826     Document Type: Article

References (49)

1. Brodeur GM and Maris JM: Neuroblastoma. In: Principles and Practice of Pediatric Oncology. Pizzo PA and Poplack DG (eds). Lippincott, Williams and Wilkins, Philadelphia, pp933-970, 2006.
2. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 341: 1165-1173, 1999.
3. Matthay KK, Reynolds CP, Seeger RC, et al: Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study. J Clin Oncol 27: 1007-1013, 2009.
4. Kirn D, Martuza RL and Zwiebel J: Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7: 781-787, 2001.
5. Parato KA, Senger D, Forsyth PA and Bell JC: Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976, 2005.
6. Vähä-Koskela MJ, Heikkilä JE and Hinkkanen AE: Oncolytic viruses in cancer therapy. Cancer Lett 254: 178-216, 2007.
7. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH and Wimmer E: Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA 97: 6803-6808, 2000.
8. Ochiai H, Campbell SA, Archer GE, et al: Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. Clin Cancer Res 12: 1349-1354, 2006.
9. Ochiai H, Moore SA, Archer GE, et al: Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin Cancer Res 10: 4831-4838, 2004.
10. Toyoda H, Yin J, Mueller S, Wimmer E and Cello J: Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res 67: 2857-2864, 2007.
11. Diaz RM, Galivo F, Kottke T, Wongthida P, et al: Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 67: 2840-2848, 2007. (Pubitemid 46548974)
12. Greiner S, Humrich JY, Thuman P, Sauter B, Schuler G and Jenne L: The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin Exp Immunol 146: 344-353, 2006.
13. Moehler MH, Zeidler M, Wilsberg V, et al: Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum Gene Ther 16: 996-1005, 2005.
14. Li H, Dutuor A, Fu X and Zhang X: Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. J Gene Med 9: 161-169, 2007.
15. Li H, Dutuor A, Tao L, Fu X and Zhang X: Virotherapy with a type 2 herpes simplex virus derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res 13: 316-332, 2007. (Pubitemid 46121885)
16. Qiao J, Kottke T, Willmon C, F. Galivo, et al: Purging metastases in lymphoid organs using a combination of antigen non-specific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 14: 37-44, 2008.
17. Toda M, Rabkin SD, Kojima H and Martuza RL: Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 10: 385-393, 1999.
18. Obeid M, Tesniere A, Ghiringhelli F, et al: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61, 2007. (Pubitemid 46067386)
19. Obeid M, Panaretakis T, Joza N, et al: Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light induced apoptosis. Cell Death Differ 14: 1848-1850, 2007.
20. Blachère NE, Darnell RB and Albert ML: Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation PLoS Biol 3: 1070-1078, 2005.
21. Cello J, Paul AV and Wimmer E: Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science 297: 1016-1018, 2002.
22. Mueller S and Wimmer E: Recruitment of nectin-3 to cell-cell junctions through trans-heterophilic interaction with CD155, a vitronectin and poliovirus receptor that localizes to alpha(v) beta3 integrin-containing membrane microdomains. J Biol Chem 278: 31251-31260, 2003.
23. Decker T and Lohmann-Matthes ML: A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 115: 61-69, 1988.
24. Koike S, Taya C, Kurata T, et al: Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci USA 88: 951-955, 1991.
25. O'Shea CC: Viruses-seeking and destroying the tumor program. Oncogene 24: 7640-7655, 2005.
26. Matzinger P: An innate sense of danger. Semin Immunol 10: 399-415, 1998.
27. Steinman RM, Turley S, Mellman I and Inaba K: The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 191: 411-416, 2000.
28. Fuchs A, Cella M, Giurisato E, Shaw AS and Colonna M: Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with poliovirus receptor (CD155). J Immunol 172: 3994-3998, 2004. (Pubitemid 38375210)
29. Pende D, Bottino C, Castriconi R, et al: PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol 42: 463-469, 2005.
30. Bottino C, Castriconi R, Pende D, et al: Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 198: 557-567, 2003.
31. Tahara-Hanaoka S, Shibuya K, Kai H, et al: Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. Blood 107: 1491-1496, 2006.
32. Seth S, Maier MK, Qiu Q, et al: The murine pan T cell marker CD96 is an adhesion receptor for CD155 and nectin-1. Biochem Biophys Res Commun 364: 959-965, 2007. (Pubitemid 350087894)
33. Rosenberg SA, Yang JC and Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915, 2004.
34. Zitvogel L, Tesniere A and Kroemer G: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6: 715-727, 2006.
35. Casares N, Pequignot MO, Tesniere A, et al: Caspase dependent immunogenicity of doxorubicininduced tumor cell death. J Exp Med 202: 1691-1701, 2005.
36. Kepp O, Senovilla L, Galluzzi L, et al: Viral subversion of immunogenic cell death. Cell Cycle 8: 860-869, 2009.
37. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M and Vile RG: Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 4: 581-587, 1998.
38. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S and Bhardwaj N: Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191: 423-434, 2000.
39. Freedman RS, Edwards CL, Bowen JM, Lotzova E, Katz R, Lewis E, Atkinson N and Carsetti R: Viral oncolysates in patients with advanced ovarian cancer. Gynecol Oncol 29: 337-347, 1988.
40. Shi Y, Evans JE and Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425: 516-521, 2003.
41. Udono H and Srivastava PK: Comparison of tumor-specific immunogenicities of stress induced proteins gp96, hsp90, and hsp70. J Immunol 152: 5398-5403. 1994.
42. Ullrich E, Bonmort M, Mignot G, Kroemer G and Zitvogel L: Tumor stress, cell death and the ensuing immune response. Cell Death Differ 15: 21-28, 2008.
43. Sinkovics J and Horvath J: New developments in the virus therapy of cancer: a historical review. Intervirology 36: 193-214, 1993.
44. Schulz O, Diebold SS, Chen M, et al: Toll-like receptor 3 promotes cross-priming to virus infected cells. Nature 433: 887-892, 2005.
45. Sinkovics JG and Horvath JC: Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts. Int J Oncol 29: 765-777, 2006.
46. Murray DR, Cassel WA, Torbin AH, Olkowski ZL and Moore ME: Viral oncolysate in the management of malignant melanoma. II. Clinical studies. Cancer 40: 680-686, 1977.
47. Cassel WA and Murray DR: A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 9: 169-171, 1992.
48. White RR, Stanley WE, Johnson JL, Tyler DS and Seigler HF: Long-term survival in 2505 patients with melanoma with regional lymph node metastasis. Ann Surg 235: 879-887, 2002.
49. Goetz C and Gromeier M: Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. Cytokine Growth Factor Rev 21: 197-203, 2010.